Q4 2021

APAC / Issue Q4 2021 5 NEWS , Sihuan Pharmaceutical Holdings Group Ltd., together with its subsidiaries and SignalChem Lifesciences Corporation today announced that Sihuan Pharmaceutical Holdings Group Ltd subsidiary company Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu”) and SignalChem Lifesciences Corporation (“SignalChem”) have entered into an exclusive collaboration and licensing agreement for the clinical development and commercialization of SLC391, a potent and selective AXL targeting inhibitor, in the Greater China region. Under the terms of the agreement, Xuanzhu will pay to SignalChem an upfront fee of thirteen million US dollars (US$13,000,000). Additional development milestones and royalties have also been committed. The exclusive rights for SLC-391 for the field of oncology is for the Greater China region (Mainland China, Hong Kong, Macau and Taiwan). AXL is a member of TAM (Tyro3, AXL, Mer) family of receptor tyrosine kinases. AXL along with its ligand GAS6 (growth arrest-specific gene 6) is highly expressed and activated in many malignant tumors, such as acute myeloid leukemia, kidney, pancreatic, breast, lung and ovarian cancer, etc. As one of the crucial signaling pathways promoting tumor growth and metastasis, immune escape and drug resistance, GAS6-AXL pathway is considered to be an attractive target for Xuanzhu and SignalChem Lifesciences Corporation Announce Collaboration and Licensing Agreement for SLC-391 in the Greater China Region cancer treatment and has attracted widespread attention. “The agreement with SignalChem will further advance Xuanzhu’s pipeline in the solid tumor and hematoma space. The results from preclinical and phase 1 clinical development demonstrated SLC391 superiority not only as SLC391 has prominent single-agent activities in multiple solid and hematological tumors but also can potentially be administered with a variety of drugs under development at Xuanzhu. Both parties will use their respective resources to accelerate the clinical approval of SLC-391 in China,” said Ms. Xu Yanjun, Chairman of Xuanzhu. “Xuanzhu will continue to expand its efforts to develop and commercialize innovative drugs in the oncology field.” “Xuanzhu Biopharmaceutical, a subsidiary of Sihuan Pharmaceutical, is a highly innovative and progressive company,” commented by Mr. Jun Yan, the Chairman and President of SignalChem, “We are very pleased to establish a partnership with Xuanzhu. This licensing agreement is of great significance for SignalChem to further validate and expand SLC-391’s clinical superiority. This agreement will accelerate SLC-391’s development timeline to reach the market and provide more effective treatment alternatives for patients with cancer.” Mr. Jun Yan added, “the size of the agreement, including upfront, milestone and royalties, with Xuanzhu may be one of the largest agreements signed in Canada with a Chinese bio-pharma company for the Chinese territory rights, and we are looking forward to reaching all anticipated objectives. Furthermore, SignalChem will continue its efforts to expand and accelerate clinical development with SLC-391 for wider indications in even more geographic territories.” intervention of mental health issues in children and young people around the world. We hope by becoming the voice of the organisation, the society will come to the realisation that mental health issues in children and young people should not be stigmatized and that there are effective interventions for youth with mental health problems. Furthermore, IACAPAP’s website has useful resources on topics related to children and young people’s mental health issues that anyone, including parents, children, young people, or even members of the media, can access for free. We will also be distributing thought leadership articles from the IACAPAP every quarter on pertinent public youth mental health issues. We hope through knowledge sharing and imparting positive messages, we can collectively make a positive difference in people’s lives. Knowledge changes perception and shape’s opinion.” Said Ms. Jennifer Kok, the Founder & CEO of Media OutReach.” Media OutReach has been supporting numerous local and international non-profit organisations which focus on social and mental wellbeing of children and young people. “We help on the premise that every child matter, regardless where they live and what skin colour they are, no child or adolescent should be neglected. They are the future of the world, and this our vision aligns with that of IACAPAP’s. We are very certain that this partnership will bring a positive impact to the society and help to change people’s attitudes towards mental health issue. More importantly, we want parents and society to regard seeking mental health advice as just the same as going to your general practitioners.” She continued. Media OutReach’s guarantee online news posting helps to make articles available to a global audience and by delivering news directly to the inboxes of relevant journalists out of 140,000 media contacts, the newswire will ensure IACAPAP’s news is readily available for journalists who would like to write or research about related topics. “With Media OutReach’s global press release distribution capabilities, we are able to make changes impactfully.” Said Ms Kok.